Sprung from the Ashes
Geron ESC Assets Regenerate at Asterias Biotherapeutics
By Marie Powers
Thursday, April 4, 2013
A 300-page S-1 filing with the SEC on Wednesday revealed that Geron Corp.'s human embryonic stem cell (ESC) assets, left dangling when the company abandoned the field in late 2011, will be reborn at Asterias Biotherapeutics Inc., a newly formed subsidiary of regenerative medicine specialist BioTime Inc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.